DreaMed Diabetes leverages Glooko diabetes management platform to deliver proprietary insulin dosing algorithms to clinicians and people with diabetes

February 3, 2016 – Palo Alto, CA and Petah Tikva, Israel – Glooko, Inc., provider of the leading unified platform for diabetes management, and DreaMed Diabetes, developer of innovative and patient-centric decision support technologies for insulin-dependent people with diabetes (PWDs), today announced a partnership to commercialize DreaMed’s Advisor algorithm using the Glooko platform. The partners will demonstrate the integrated solution at the Advanced Technologies & Treatments for Diabetes (ATTD) conference, from 3 – 6 February 2016 in Milan, Italy.

Glooko and DreaMed aim to vastly improve insulin management for over 30 million people with Type 1 diabetes globally [1], about 35% of whom currently use insulin pumps [2]. Glooko’s diabetes platform enables a PWD to download and visualize data from their diabetes device using their mobile phone and makes this data available to clinicians via the secure cloud. With the integration of DreaMed’s MD – Logic Pump Advisor into Glooko’s platform, insulin pump data can be assessed for patterns that yield personalized recommendations for critical pump-related settings, including basal rates and insulin-to-carb ratios. These recommendations are made available to clinicians via Glooko’s Population Management application, which allows a review of the therapeutic basis behind the recommended adjustment. Once approved, the recommendations are made available via the Glooko app on the PWD’s mobile phone.

For Glooko, the collaboration with DreaMed Diabetes is an initial step towards the company’s broader initiative to cultivate an ‘app store for diabetes algorithms and tools’, all of which leverage Glooko’s robust diabetes data engine and mobile app/web capabilities. “Clinicians, mathematicians, and data engineers from universities and companies worldwide have been developing algorithms capable of using diabetes data to micro-optimize each component of diabetes management, from insulin pump settings to dietary choices” said Rick Altinger, Glooko CEO. He continued, “Enabling partners to use Glooko’s vast diabetes dataset to deliver personalized insights at the patient level will give clinicians the information they need to provide impactful recommendations that can improve health outcomes.”

By allowing diabetes decision support tools to be built on the Glooko platform, the company is carving a path for PWDs and clinicians to get access to innovative technology to help improve their overall decision making. At the same time, Glooko provides a scalable way to enable organizations that create these algorithms to test, improve and ultimately commercialize them, bringing innovation to the forefront of positively impacting the lives of people with diabetes.

DreaMed CEO, Eran Atlas, said “We are very gratified to be collaborating with Glooko on the first commercialization project for our Advisor technology. Together, we will transform critical diabetes data into actionable information, giving healthcare providers a clinically effective, patient-specific decision support tool. Our collaboration is designed to raise the bar for fast, efficient and personalized medicine, by providing both doctors and diabetes patients with a holistic, simple glucose balancing solution.”

The partnership with Glooko is part of DreaMed’s overall strategy to transform Advisor into a necessary analytical component in any diabetes management system offering advanced personalized medicine. Future collaborations will include partnering with stakeholders that generate, collect and store patient data, to provide real-time glucose balance and behavioral guidance. Such collaborations can transform collected data into actionable information, with the aim of enabling DreaMed partners to provide more holistic and simple solutions for diabetes patients.

[1] IDF Diabetes Atlas – Sixth Edition

[2] T1D Exchange – Insulin Pump Use Varies Across Globe Despite Benefits in Diabetes Control

ABOUT GLOOKO
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant web and mobile application, which aims to improve health outcomes for people with diabetes, in turn reducing costs for payers and the healthcare system. Glooko seamlessly syncs with over 40 blood glucose meters, pumps, CGMs, fitness and activity trackers, and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s Population Management web app and API’s offers diabetes-centric analytics and supply insightful reports, graphs and risk flags to patients, health systems and payers, as well as third party developers. Learn more at https://glooko.com , and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko .

ABOUT DREAMED DIABETES
DreaMed Diabetes, established in 2014, is dedicated to empowering insulin-dependent patients and their doctors with innovative and patient-centric decision support technology. The DreaMed Diabetes team includes thought-leading endocrinologists, biomedical engineers, and software developers with more than 50 years of combined field experience. With its innovative multidisciplinary approach, DreaMed Diabetes developed MD – Logic Technology – sophisticated algorithms which analyze available real-world data on dosing and glucose levels, in addition to patient reporting, emulating the way expert endocrinologists actually evaluate their patients. DreaMed became the first company in the world to receive CE Mark approval for artificial pancreas technology (Glucositter), as well as the first to conduct artificial pancreas studies under real-world conditions. DreaMed is bringing optimal glycemic control to patients with diabetes everywhere, with personalized medicine that improves their quality of life and lowers their overall treatment costs. Learn more at http://www.dreamed – diabetes.com and follow us at Twitter.com/DreaMedDiabetes.

Recent results on the effectiveness of Glooko-enabled Patient Remote Monitoring and Diabetes Self-Management Presented on October 22, 2015 at the Diabetes Technology Meeting

Thursday, Oct 29, 2015 – Palo Alto, CA – Glooko, the leading unified platform for diabetes management, today  announced that Glooko was featured in a poster presentation on the effectiveness of Glooko-enabled Type 2 diabetes management resulting from a pilot conducted at the Diabetes & Glandular Disease (DGD) Clinic. Based in San Antonio, Texas, DGD is the one of the largest Type 2 adult endocrinology facilities in the country. The presentation, given by Dr. Jerome Fischer, a partner and Endocrinologist at DGD, occurred during the scientific poster session at the Diabetes Technology Meeting on October 23, 2015 in Bethesda, MD.

The twelve-week pilot measured the effectiveness of using Glooko, which enables data-driven clinical interactions between clinician and patient via the Glooko mobile app and Glooko Population Tracker, to facilitate remote monitoring and coaching of Type 2 patients by nurse practitioners at DGD (intervention group). The intervention group was compared with a control group in which Type 2 patients used Glooko alone for diabetes self management (along with treatment as usual).

Both the intervention and control groups experienced a statistically significant improvement in mean blood glucose and glycemic variability. Notably, subjects who experienced three or more Glooko-facilitated remote clinical interactions with a nurse practitioner experienced a significantly better improvement in mean blood glucose compared to control subjects.

In a post-pilot survey, 96% of responding subjects said Glooko made it easier to adhere to their diabetes therapy regimen. In addition, 81% of responding subjects reported receiving therapy recommendations during their remote clinical interactions; these interactions regularly included insulin and medication adjustments. “Improving the quality, frequency and cost of clinical interactions between the clinician and patient is crucial for optimizing diabetes management,” said Rick Altinger, Glooko CEO. For information on pilot results or a copy of the poster presentation, contact [email protected].

About Glooko
Glooko is the Unified Platform for Diabetes Management and provides an FDA-cleared, HIPAA-compliant Web and Mobile application for diabetes patients and clinicians which improves outcomes and lowers costs. The platform seamlessly unifies data from over 50 of the leading blood glucose meters, insulin pumps, continuous glucose monitors, activity trackers and biometric devices to deliver insights that improve personal and clinical decision support. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and pattern-triggered notifications to patients, health systems and payers. The Glooko platform also allows customers and third party developers to create branded modules for Glooko users. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc , and Facebook.com/Glooko .

Glooko PR
Contact
Vikram Singh
[email protected]

Integration enables wireless download of blood glucose data for on-demand insights and alerts

Palo Alto, Calif. – September 24 , 2015 – Glooko Inc., the leading unified platform for diabetes management, today announced general availability of its integration with Roche ’s Accu-Chek Aviva Connect blood glucose meters to send blood glucose (BG) results automatically to the Glooko platform. Through wireless Bluetooth Smart technology built into these Accu-Chek Aviva Connect meters, the release enables near real-time syncing of blood glucose data to the Glooko platform without the need to connect cables. Data syncing happens in the background directly after blood glucose readings are measured by people using an Accu-Chek Aviva Connect meter.

With this latest integration, Glooko addresses a long-standing deterrent to tracking blood glucose trends: manual entry and syncing of blood glucose data into apps and disease management systems to help patients and clinicians better manage diabetes. When people with diabetes use a Bluetooth enabled Accu-Chek Aviva Connect meter, they simply have to check their blood glucose and their data becomes automatically available in Glooko, where it is combined with exercise, diet, CGM, pump and medication data in a series of reports and analytics.

Traditional mobile health solutions that require manual entry of BG data have struggled to capture accurate data and keep users engaged, resulting in missing data points and an inability to review accurate glucose trends necessary for diabetes decision making. With its support for Accu-Chek Aviva Connect meters, Glooko builds on its device-agnostic platform, which is focused on making diabetes management easier through data accessibility and advanced analytics.

“We are excited that Glooko has chosen to add the Accu-Chek Aviva Connect meter to its platform”, said Laura Spiegel, Group Marketing Manager of Strategy and Innovation at Roche Diagnostics Corporation. “By adding our Bluetooth enabled meter to its lineup, Glooko is able to leverage seamless access to blood glucose data in order to deliver actionable information that is accessible near real time. Individuals using Accu-Chek Aviva Connect can easily share this information with their care team to support better decisions and care adjustments for positive health outcomes.”

With this new integration to the Glooko platform, a patient’s family members and their care team can use the Glooko mobile and web apps to remotely monitor their blood glucose as well as other important information, such as insulin, carb and fitness data in a single platform. The patient’s care team can also access this information and connect with patients who require more attention. “ In situations where a patient is experiencing dangerous hypoglycemic events, Roche’s seamless transfer of blood glucose data through Glooko in near real time to the smartphone triggers Glooko to engage patients in creating better hypoglycemic awareness via the Joslin HypoMap™ survey and other pattern recognition features, giving patients and their care teams the ability to actively mitigate these issues,” said Michelle de Haaff, Glooko’s Vice President of Marketing.

To learn more about what blood glucose, pump, CGM, exercise and mobile devices that Glooko integrates with, visit our website compatibility page.

The Accu-Chek Aviva Connect meter can found exclusively at Walgreens nationwide.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For 40 years, the Accu-Chek brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals manage their patients’ condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management. It encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome. For more information: www.accu-chek.com .

All trademarks used or mentioned in this release are legally protected.

About Glooko
Glooko is the Unified Platform for Diabetes Management and provides an FDA-cleared, HIPAA-compliant Web and Mobile application for diabetes patients and clinicians, which aims to improve outcomes and lowers costs. The platform seamlessly unifies data from over 50 leading blood glucose meters, insulin pumps, continuous glucose monitors, activity trackers and biometric devices to deliver insights that improve personal and clinical decision support. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and APIs offers diabetes-centric analytics and supplies insightful reports, graphs and pattern-triggered notifications to patients, health systems and payers. The Glooko platform also allows customers and third party developers to create branded modules for Glooko users. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc  and Facebook.com/Glooko .

Press Contact:
Vikram Singh
[email protected]

Medical advisory board charged with helping to advance the Glooko unified diabetes management platform and advise Glooko on clinical studies

Palo Alto, Calif. ​ – July 9, 2015 ​ – ​Glooko Inc​., the leading unified platform for diabetes management, today announced the formation of its first Medical Advisory Board who will provide Glooko with clinical expertise in the area of diabetes analytics and clinical studies.

Comprised of a highly accomplished group of physicians from leading institutions across the United States, the Medical Advisory Board will share their extensive expertise in clinical engagement, diabetes devices, patient outcomes analytics, population management and other areas important to Glooko’s clinical studies, product development and strategic initiatives.

“As Glooko continues to deliver a unified platform for diabetes management, ​this board will be central in helping us to continue to deliver clinically relevant insights and outcome studies to drive increasing value to Provider Health Systems and the patients they serve”, said Rick Altinger, Glooko, CEO.

He continued, “We are thrilled by both the expertise and caliber of the members of our newly formed medical advisory board. Their complementary backgrounds and experiences, coupled with their expertise and innovative approaches to clinical practice will help to keep Glooko on the cutting edge.”

The five ­member board, chaired by Glooko’s Chief Medical Officer, Dr. Michael Greenfield, includes:

Dr. Mark Clements, MD, PhD -​ Associate Professor of Pediatrics, University of Missouri-­Kansas City School of Medicine, Children’s Mercy Hospitals, Kansas City, MO
Specializing in glucose variability, diabetes care technology and chronic complications in diabetes, Dr. Clements, MD, PhD and AAP fellow, brings a passion for data analytics and insights to his pediatric endocrinology practice at Children’s Mercy Hospitals and is known as a diabetes care innovator for the children he treats.

Dr. Jerome Fischer, MD­ – Diabetes and Glandular Disease Clinic (DGD), Clinical Instructor, University of Texas Health Science Center, San Antonio, TX

An accomplished researcher, partner and CIO of the DGD Clinic in San Antonio, TX, Dr. Fischer, MD has been involved as investigator in numerous research trials and is considered a leader in the most progressive use of diabetes education combined with technology and cutting-­edge treatments to serve diabetes patients in Southern Texas.

Dr. Michael Greenfield, ​MD -­ Glooko Chief Medical Officer, Endocrinologist, El Camino Hospital, Palo Alto, CA

Glooko Chief Medical Officer and diabetes technology expert, Dr. Greenfield, MD helps to lead the Glooko effort to create patient and clinical relevant and innovative analytics. Dr. Greenfield chairs the IRB at El Camino Hospital in Silicon Valley, completed his endocrine training at Stanford and is an accomplished researcher and a beloved clinician.

Dr. David Kerr, MD – Director of Diabetes Research and Innovation, Sansum Diabetes Research Institute, Santa Barbara, CA
Dr. David Kerr, MD is a UK trained physician and endocrinologist, a former diabetes ​ researcher at Yale and the former Editor of the Journal of Diabetes Science and Technology. Dr. Kerr is a Fellow of the Royal College of Physicians of Edinburgh, visiting Professor at Bournemouth University and has held a Gold Clinical Excellence Award from the National Health Service in the UK.

Dr. Howard Wolpert, MD -­ Director, Institute for Technology Translation, Joslin Diabetes Center & Associate Professor, Harvard Medical School, Boston, MA
A world­-renowned diabetes researcher and clinician, Dr. Howard Wolpert, MD has focused on the use of technology in intensive diabetes management. He established and directed the Insulin Pump & Continuous Glucose Monitoring Programs at the Joslin Clinic, and had been principal investigator in several multi­center randomized controlled trials. He is one of two foreign members of the Scientific Advisory Board of the European Union­-funded academic/industry collaborative on diabetes technology.

As Glooko’s international expansion continues we look forward to inviting several international thought leaders from around the globe to join the Glooko Medical Advisory Board.

With the decline of board certified endocrinologists, coupled with projected increases in diabetes population growth, the ability to care for diabetes patients is more and more falling on primary care and family care physicians. Through Glooko’s Population Management and Office Kiosk applications, endocrinologists and primary care physicians will have the data and insights they need to more efficiently and effectively treat patients with Type 1, Type 2 and gestational diabetes, enabling them to scale quality delivery of medical services, improve overall diabetes outcomes and ultimately lower the overall cost of serving the diabetes population.

This announcement comes on the heels of Glooko’s ​recent Series B investment ​that brought $16.5M of additional funds into the business. The investment will be used to fuel expansion of the Glooko platform to include device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms that enable both patient and provider decision support.

About Glooko
Glooko is the ​Unified Platform for Diabetes Management ​and provides an FDA-­cleared, HIPAA­-compliant Web and Mobile application for diabetes patients and clinicians which improves outcomes and lowers costs. The platform seamlessly unifies data from over 50 of the leading blood glucose meters, insulin pumps, continuous glucose monitors, activity trackers and biometric devices to deliver insights that improve personal and clinical decision support. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes­-centric analytics and supplies insightful reports, graphs and pattern­-triggered notifications to patients, health systems and payers. The Glooko platform also allows customers and third party developers to create branded modules for Glooko users. Learn more at​ https://glooko.com and follow us at ​Twitter.com/GlookoInc, and Facebook.com/Glooko.

Glooko PR Contact
Vikram Singh
[email protected]

Medtronic Aims to Provide People with Diabetes, Their Care Teams and Healthcare Providers with Greater Insights to Improve Care

BOSTON – June 5 , 2015 – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced an agreement with Glooko, the trusted leader in diabetes data unification and analytics, to improve access to meaningful diabetes health data in a safe and secure way. The partnership will incorporate information from Medtronic insulin pumps and continuous glucose monitors (CGM) into Glooko’s secure, unified, cloud and mobile-based diabetes management platform. In addition, Medtronic will be able to integrate other health and wellness data sources, such as food, medication, fitness and biometric data with its CareLink platform. Combining this with insulin and CGM data could provide additional insights for patients and providers and could be beneficial to improve diabetes management.

Medtronic aims to provide holistic diabetes management solutions that optimize both clinical outcomes and health economics, which will rely on the safe and secure sharing of diabetes data across the care continuum. Both companies are exhibiting at American Diabetes Association 75th Scientific Sessions: Medtronic at Booth #437 and Glooko at Booth #104.

Medtronic’s decision support software, CareLink, has provided an incredible amount of compelling diabetes data along with an understanding of diabetes care pathways. Now, in addition to viewing insulin and glucose data through Medtronic’s Carelink system, people with diabetes and their healthcare providers will also be able to access this information through Glooko, who will integrate it with other health data to offer a unified view to patients and their care teams to better make both day-­to-day and longer term decisions. Glooko leverages mobile and web based views to organize all the information into consolidated analytics and insights that enable patients and healthcare providers to understand the impact of carbs and insulin, combined with other variables like exercise and biometric data.

“Our goal is to provide people with diabetes, their care teams and healthcare providers with actionable insights that improve decision-making to optimize care. By partnering with the Glooko diabetes management platform, we can provide safe and secure access to meaningful diabetes information to our customers that goes beyond just device data,” said Annette Brüls, vice president and general manager, Diabetes Services and Solutions at Medtronic. “ Combining the additional data collected by Glooko with our CareLink data will enable further insights into how various health and fitness activities affect insulin therapy. The Glooko partnership is part of our overall strategy to move towards a holistic diabetes management company and use our leading technologies, data and informatics to enable better therapy decision making and care for people with diabetes, to enable greater freedom and better health.”

“Medtronic customers and their healthcare teams can leverage the Glooko unified platform to improve outcomes and reduce costs by leveraging mobile and cloud based technology to better understand and act on insights to improve their care plan and lifestyle,” said Rick Altinger, CEO of Glooko. “Working together we will bring information from Medtronic insulin pumps and continuous glucose monitors, along with food, medication, fitness and biometric data, to offer a unified view and actionable insights to patients and their care teams.”

With Medtronic data available in the Glooko diabetes management platform, healthcare systems will be able to provide more proactive care across the broadest set of patients. Glooko will also allow healthcare systems to identify blood glucose patterns that represent actions that can be improved (such as altering insulin bolus levels) or flagging at-risk patients among their patient population.

About Glooko
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 30 blood glucose meters, the world’s major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and risk flags to health systems and payers. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko .

About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland, is the global leader in medical technology–alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronicʹs periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Addition of Insulin Pump & CGM data , used for intensive glucose management of Type 1 and Type 2 diabetes, enhances utility of Glooko’s remote monitoring and predictive glucose analytics tools for high-risk diabetes patients and their healthcare providers .

Palo Alto, Calif. – June 3 , 2015 – Glooko Inc. today announced it will demonstrate its integration with Insulin Pumps and Continuous Glucose Monitors (CGMs) at the American Diabetes Association’s 75 th Scientific Sessions , adding to the diabetes population management platform’s existing support for 30+ blood glucose meters, popular activity trackers, and biometric monitors for blood pressure and weight . Glooko’s presence at the conference, occurring June 4-8, 2015 in Boston, MA, will include a presentation at the Insulet booth as well. Glooko will demonstrate it’s end-to-end platform at booth #104.

Glooko’s integration with insulin pumps and CGMs meets the growing demand from ACOs and progressive health system s for on-demand, remote access to diabetes data associated with the significant subset of their diabetes population requiring regular glucose monitoring and tight regulation of insulin levels. According to The Diabetes Device Market Outlook to 2016 published by Business Insights, insulin pumps, which deliver rapid-acting insulin 24 hours a day through a catheter placed under the skin, are used by 33% of people with Type 1 diabetes , while CGMs, used to measure glucose levels in real-time throughout the day and night, are expected to be used by up to 25% of people with Type 1 diabetes in 2016. The study indicates that t he projected market valuation associated with the se diabetes devices in 2016 is $2.9B and $763M, respectively.

“Utilizing Glooko’s remote monitoring functionality, ACOs and health systems can access risk-stratified patient data on-demand after a patient syncs his or her diabetes device to a smartphone ,” said Rick Altinger, Glooko’s CEO. He continued, “With Glooko’s addition of Pumps and CGMs, care teams can better track and manage people who are starting or continuing intensive insulin therapy to improve their overall care which may ultimately improve their health outcomes.”

In conjunction with supporting Insulin Pumps and CGMs, Glooko has added the ‘Pump Day View’ and ‘Pump Insights’ as new functionality to its platform. The ‘Pump Day View’ will allow seamless correlation amongst a patient’s basal and bolus insulin records, carb intake, exercise, and glucose readings from the patient’s CGM or blood glucose meter. The ‘Pump Insights/Settings’ view provides clarity on the impact of pump suspends, temporary basal events, and site changes on blood glucose levels. By leveraging Glooko’s diabetes device agnostic approach, ACOs, health systems, and people with diabetes can visualize data from their preferred combination of insulin pumps, CGMs, blood glucose meters, and fitness trackers in Glooko’s standardized, best-in-class diabetes data views.

In conjunction with the ADA conference, Glooko will be presenting at The DiabetesMine D-Date Exchange meeting on Friday, June 5th, held at the Cambridge Innovation Center. The company will also be sponsoring the 9th Annual ADA Forum, hosted by diaTribe and TCOYD, at the Seaport Boston Hotel on Monday, June8th.

About Glooko, Inc.
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application, which aims to improve health outcomes for people with diabetes, which may in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 4 0 blood glucose meters, pumps (coming soon or currently in the design phase), CGMs (coming soon or currently in the design phase), fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and risk flags to health systems and payers. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc , and Facebook.com/Glooko.

For More Information
Vikram Singh
Glooko PR
[email protected]

Leverages recent investment to fuel expansion of its Unified Platform for Diabetes Management by continuing to add data from diabetes devices

Palo Alto, Calif. – June 3, 2015 – Glooko Inc. today announced partnerships with Dexcom, Inc., developer and marketer of a continuous glucose monitoring (CGM) system, and with Insulet Corporation, the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System. These partnerships are another step in Glooko’s efforts to unify all diabetes relevant device data into a single, unified platform to enable both patients and healthcare providers to improve health outcomes.

“Digital health data integration will have a significant impact on the clinical care we provide for people with diabetes,” said Dr. Howard Wolpert of the Joslin Diabetes Center.” Our work with Glooko in creating the Joslin HypoMap powered  y Glooko and Glooko continuing to add in device data and reports that synthesize information to provide clinically significant insights not present on currently-available data downloads will help more patients to realize the benefits of CGM and pump therapy, and will help clinicians provide more efficient and effective care,” he continued.

Glooko will deliver its next generation product that includes both Dexcom CGM and Insulet’s OmniPod pump data this summer, adding data from both systems into it’s unified platform that already syncs data from more than 30 blood glucose (BG) monitors (over 90% market share) and the most popular fitness and biometric tools with patient’s Apple or Android mobile devices. Patients can also record food intake and medication and insulin dosage to provide context around changes in their blood glucose readings.

“We are pleased to be partnering with Glooko to add Dexcom CGM data to their comprehensive diabetes management platform,” said Kevin Sayer, CEO of Dexcom. “We believe that Glooko’s platform which accesses Dexcom data through our ‘open architecture’ can be a very meaningful tool for our patients to manage their diabetes.”

Dexcom’s CGM data and Insulet’s OmniPod’s pump data will be brought into Glooko and structured for patients and their healthcare providers in a simple to interpret view in both the Glooko mobile app and in a risk-stratified view via Glooko’s Population Tracker™. Glooko will access data from these devices directly, in addition to pulling data from the Apple Healthkit. Glooko enables healthcare providers to engage at-risk patients before costly intervention and hospitalizations occur. In addition, Glooko allows healthcare providers and patients to understand and analyze their diabetes data, and set reminders for improved treatment plan adherence.

“Now OmniPod patients will have the ability to view their insulin delivery, blood glucose and CGM data together,” said Patrick Sullivan, President and Chief Executive Officer of Insulet Corporation. “Patients will have access to data that will allow them to take full advantage of the clinical benefits that the OmniPod system provides while still providing the freedom of the unique, tubeless insulin delivery system. This collaboration furthers our shared vision of helping to make life with diabetes easier by providing greater access to the data people living with diabetes need to make smart and effective decisions to realize better control.”

This announcement comes on the heels of Glooko’s recent Series B investment that brought $16.5M of additional funds into the business. The investment will be used to fuel expansion of Glooko’s FDA-cleared, HIPAA-compliant platform to include device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms.

Glooko is demonstrating its integration with both the Dexcom CGM and the Insulet OmniPod Insulin Management System in booth #104 at the American Diabetes Association’s Annual Scientific Conference from June 5 – 9 at the Boston Convention and Exhibition Center in Boston, MA. They are scheduled to release the integrated product for public consumption later in the summer o f 2015.

About Glooko , Inc.
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application, which aims to improve health outcomes for people with diabetes, which may in turn reduce costs for payers and the healthcare system. Glooko seamlessly syncs with over 30 blood glucose meters, pumps, CGMs, fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and risk flags to patients, health systems and payers, as well as, third party developers . Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc , and Facebook.com/Glooko .

About Dexcom , Inc.
DexCom, Inc., ( NASDAQ: DXCM ) headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers in the hospital. For more information visit: http://dexcom.com/

About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod® Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet’ s subsidiary, Neighborhood Diabetes, is a leading distributor of diabetes products and supplies, delivered through a high touch customer service model. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit Insulet’s customer blog, Suite D: http://suited.myomnipod.com . Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts.For more information, please visit: http://www.myomnipod.com .

For More Information
Vikram Singh
Glooko PR
[email protected]

Diabetes management platform leverages recent investment to grow leadership bench with experienced executives

Palo Alto, Calif. – April 23, 2015 – Glooko Inc., the leading unified platform for diabetes management, today announced the addition of two new executives to its management team. Serdar Akin joins as Vice President of Development and Michelle de Haaff joins as Vice President of Marketing and Customer Success. Both executives come on-board with years of experience in product delivery, marketing and customer experience.

Serdar joins Glooko after 15 years in executive roles at Symantec’s Global Enterprise Security Group and at Intuit Health where he led product management and user experience design. He oversaw a portfolio of products that served over 60,000 healthcare providers and 7 million patients. Mr. Akin was a principal driver behind expanding Intuit’s healthcare focus to include healthcare provider services. This effort resulted in the acquisition of Medfusion, the leading supplier of patient-healthcare provider communication and portal services. At Glooko, Serdar will lead the product management and development team and will focus on continuing to expand the Glooko Unified Platform to include additional device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms.

“Glooko is at a unique time of strong growth and increasing patient and provider engagement,” said Mr. Akin. “I am excited to lead the development team towards continuing to deliver a secure, scalable and intuitive software platform that can improve the lives of people with diabetes and provide management and remote monitoring tools for their care team.”

Michelle joins Glooko after 18 years spent in the customer experience and analytics software industry. She recently came to Glooko from Medallia, an enterprise customer experience SaaS company where she led marketing globally through Medallia’s explosive market growth. Prior to Medallia she led the product, marketing and customer engagement teams at Attensity Software, a SaaS text analytics company. She also led product management at Blue Martini Software, an eCommerce and web analytics company, from its early years through its IPO. Prior, she was a CRM practice leader with Ernst and Young Management Consulting. Her expertise is in the cross section of analytics and customer engagement. Michelle is a passionate and proven leader in the practice of creating customer success. At Glooko, she is building a Glooko customer success team that is focused on ensuring that Glooko’s customers – both patients and healthcare providers – have the optimal customer experience using Glooko.

“I believe Glooko will have impact at a global scale. Millions of people with diabetes and their healthcare providers will have the data and insights they need to make better daily decisions about personal lifestyle choices,” Michelle explained. “Additionally, Glooko is hitting an inflection point – where healthcare doesn’t just happen when a person visits the doctor or is hospitalized, but instead happens 24x7x365 and leverages on-demand data to proactively improve overall health outcomes,” she noted.

“We are collectively very happy about the new energy, ideas, skills and ‘roll up their sleeves’ attitude that both Serdar and Michelle bring to Glooko,” said Rick Altinger, CEO of Glooko. “Serdar’s background in product delivery combined with Michelle’s ability to empathize with and create great customer experiences will take Glooko to the next level in our ability to make diabetes management easier for both patients and their care team,” continued Rick.

This announcement comes on the heels of Glooko’s recent Series B investment that brought $16.5M of additional funds into the business. The investment will be used to fuel expansion of Glooko’s FDA-cleared, HIPAA-compliant platform to include device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms.

About Glooko
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 30 blood glucose meters, the world’s major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and risk flags to health systems and payers. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc , and Facebook.com/Glooko.

Contact:
Vikram Singh
[email protected]
925-487-1461

Investment to Fuel Expansion of Diabetes Device Integrations and Clinical Applications Built on Leading Mobile and Population Diabetes Management Platform

Palo Alto, Calif. – March 17 , 2015 – Glooko Inc. today announced that it has raised $16.5 Million in Series B financing. The funds will be used to expand the company’s FDA-cleared, HIPAA-compliant platform to include device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms. Canaan Partners and Medtronic joined existing investors including The Social + Capital Partnership and Samsung in the financing. As part of this round, Canaan Partners’ Wende Hutton has joined the Glooko Board of Directors.

“The healthcare industry is at an inflection point with the advent of the Affordable Healthcare Act and increased demand for better quality care without raising costs. Companies that are able to offer unprecedented access to actionable patient information combined with intuitive mobile applications are poised to meet those demands,” noted Wende Hutton, General Partner at Canaan Partners. “Glooko is the perfect example of a company that goes beyond developing a simple wearable or mobile phone app they have delivered a solution that improves patient outcomes by engaging both patients and their healthcare providers to more easily manage and gain insights from the often complex web of diabetes devices.”

Glooko’s unified diabetes management platform enables patients to better manage their diabetes and their healthcare providers to proactively engage their diabetes populations via a mobile, cloud-­based platform. Using Glooko’s bluetooth-­enabled MeterSync device, patients are already able to sync data from more than 30 blood glucose monitors (over 90% market share) with their Apple or Android mobile device. This data is then structured for providers in a simple to interpret, risk-stratified view via Glooko’s Population Tracker™, a population management tool, and via integration into other platforms, such as an Electronic Health Record (EHR). Glooko allows healthcare providers to engage at-risk patients before costly intervention and hospitalizations occur. In addition, Glooko allows healthcare providers and patients to create reminders for improved treatment plan adherence, integrate data from popular fitness trackers and biometric tools, and allow patients to record food intake and insulin dosage to provide context around changes in their blood glucose readings.

Glooko has already partnered with leaders in diabetes care, including the globally renowned Joslin Diabetes Center, and US care leaders such as the Diabetes & Glandular Disease Clinic (DGD) and Atrius Health, to name a few. Providers, health systems and payers can currently track patient progress, proactively manage and take action with at-risk patients and drive intervention programs with Glooko. By adding data from insulin pumps, continuous glucose monitoring systems and integrating personalized predictive algorithms in to its platform, Glooko will bring more utility to patients who require intensive, day-to-day glucose management, and make it easier for healthcare providers to get a full picture of a patient’s health so they can proactively treat them.

“Glooko has taken the power of mobile, cloud and analytics innovation to deliver an application that has real, daily use in helping improve the health of patients with diabetes,” said Rick Altinger, CEO of Glooko. “We have successfully attracted partnerships and investments from leaders in diabetes healthcare to join our mission in creating easy-to-use and intelligent software that adds utility for patients, healthcare providers, pharmaceutical companies and payers. The new investment will further bolster our leadership position in this area.”

About Glooko
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system . Glooko seamlessly syncs with over 30 blood glucose meters, the world’s major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and risk flags to health systems and payers. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc, and Facebook.com/Glooko.

About Canaan Partners
Canaan Partners is a global venture capital firm that invests in entrepreneurs with visionary ideas. With $4.2 billion under management and over 160 exits to date, Canaan has funded some of the world’s leading technology companies. Recent exits include Len ding Club, Ebates, and Skybox Imaging, as well as healthcare stars like Chimerix, Durata Therapeutics and Civitas Therapeutics. Current technology investments include Cardlytics, Instacart, Kabam and SOASTA, and current healthcare investments include Arvin as, CytomX, ChronoThera and Truveris.

For more info, visit canaan.com.

Contacts

Vikram Singh
[email protected]
925-487-1461

Carolyn Hawley
[email protected]
619-849-5375

Palo Alto, Calif – Nov 12th, 2014 – Glooko Inc., announced today the integration of activity, weight and blood pressure data from leading wearable activity and biometric trackers into its mobile, software as a service (SaaS) diabetes remote monitoring and population management platform. For the first time, data from fitness monitors including Fitbit, iHealth, Jawbone, Moves, RunKeeper, Strava, and Withings can be correlated and visualized against the verified blood glucose readings that Glooko currently liberates from more than 30 popular blood glucose meters using its MeterSync™ Blue technology.

With this latest innovation Glooko addresses the long-standing challenge faced by patients with diabetes of monitoring physical activity and food intake, in addition to their blood glucose levels, all of which are paramount to diabetes and chronic disease management. Physical activity has a significant impact on a patient’s blood glucose level so now patients and their care team will more clearly see the cause and effect relationship between the two. Traditional mHealth solutions requiring manual entry of this data have struggled to deliver the accuracy required for health systems and payer groups to cost – effectively engage their diabetes populations. Glooko builds on its device-­agnostic platform focused on data accessibility and advanced analytics for diabetes management.

“Physical activity is one of the major causes of hypoglycemia in individuals with diabetes. Daytime exercise will often have a delayed effect on the glucose levels and lead to nighttime hypoglycemia,” said Howard Wolpert, MD, Director of the Joslin Institute of Technology Translation. “The integration of activity data from wearable devices into the Glooko-­Joslin HypoMap system will help individual patients identify their own individual specific activity threshold that is predictive of overnight lows. We will be able to provide patients with alerts when they reach their hypoglycemia risk threshold, so that they can take preemptive steps – such as adjusting their insulin doses or eating a snack – to prevent hypoglycemia. This is one of the first steps in our vision of building a diabetes care ecosystem that will provide remote, intelligent, 24-7 guidance to patients with diabetes everywhere.”

“Access to biometric data like activity and blood pressure means our platform can be used to correlate blood glucose to lifestyle behavior to a degree not previously possible,” added Rick Altinger, Glooko CEO. “In the future, Glooko intends to use physician prescriptions to drive algorithms that utilize a patient’s level of activity along with retrospective glucose levels to make medication and insulin adjustment recommendations.”

About Glooko Inc.
Glooko is an innovative Silicon Valley company that delivers a FDA-cleared, HIPAA-compliant SaaS and mobile platform designed to improve health outcomes for people with diabetes and reduce the costs associated with diabetes population management. Glooko’s analytics and care management platform includes direct integration to all major glucose meters and other health devices to supply timely, verified patient data such as blood glucose, carbs, insulin, activity, blood pressure, and weight data. Glooko executes diabetes-centric analytics and supplies standardized reports, risk flags and insights to health systems and payers via API’s and web-­based tools.

Glooko was founded in 2011 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Chamath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Ventures, Judy Estrin, and Dr. Russell Hirsch